Oncology

Trastuzumab Biosimilar and Pertuzumab Effective, Safe in Neoadjuvant Breast Cancer Therapy

September 19th 2024

By Cameron Santoro

The combination of trastuzumab biosimilar and pertuzumab with chemotherapy was effective in treating HER2-positive breast cancer, offering high safety and affordability.

Manitoba Adopts Biosimilar Switching Policy

August 7th 2024

By Skylar Jeremias

Article

Manitoba’s new policy means that all 10 Canadian provinces now have an initiative to boost biosimilar adoption and savings by transitioning patients on reference agents to biosimilar options.

Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline

August 3rd 2024

By Skylar Jeremias

Article

Products in line to face biosimilar competition are projected to increase their list prices in advance, according to Vizient’s Pharmacy Market Outlook Report for Summer 2024.

Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval

July 24th 2024

By Skylar Jeremias

Article

Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.

PBMs Drive Up Drug Costs, Squeeze Out Generics and Biosimilars, FTC Report Finds

July 12th 2024

By Mary Caffrey

Article

A long-awaited report from the Federal Trade Commission (FTC) finds that vertical integration and consolidation have worked against consumers and independent pharmacies.

Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer

July 9th 2024

By Skylar Jeremias

Article

A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.

Biosimilars Oncology Roundup for June 2024—Podcast Edition

July 7th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.

Eye on Pharma: New Data, Clinical Developments, and Biosimilar Partnerships

July 4th 2024

By Skylar Jeremias

Article

As Celltrion publishes phase 3 data on its tocilizumab biosimilar, other companies finalize partnerships, and Formycon begins development for a pembrolizumab biosimilar.

Biosimilars Oncology Roundup: June 2024

July 2nd 2024

By Skylar Jeremias

Article

As the weather heats up for the US and Europe, so too did the biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.

EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions

June 27th 2024

By Skylar Jeremias

Article

Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.